Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdelkarim H, Boyd MR, Gorman G, Manne U, Bae S, El-Rayes BF, Piazza GA. Foote JB, et al. Among authors: maxuitenko yy. Cancer Res. 2025 Mar 3;85(5):956-972. doi: 10.1158/0008-5472.CAN-24-0323. Cancer Res. 2025. PMID: 39700396
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Foote JB, Mattox TE, Keeton AB, Chen X, Smith F, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponenko V, Abdelkarim H, Boyd MR, Gorman GS, Manne U, Bae S, El-Rayes BF, Piazza GA. Foote JB, et al. Among authors: maxuitenko yy. bioRxiv [Preprint]. 2024 Oct 7:2023.05.17.541233. doi: 10.1101/2023.05.17.541233. bioRxiv. 2024. Update in: Cancer Res. 2025 Mar 03;85(5):956-972. doi: 10.1158/0008-5472.CAN-24-0323. PMID: 38328254 Free PMC article. Updated. Preprint.
Assessment of KRASG12C inhibitors for colorectal cancer.
Piazza GA, Chandrasekaran P, Maxuitenko YY, Budhwani KI. Piazza GA, et al. Among authors: maxuitenko yy. Front Oncol. 2024 Jun 24;14:1412435. doi: 10.3389/fonc.2024.1412435. eCollection 2024. Front Oncol. 2024. PMID: 38978742 Free PMC article. Review.
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.
Sigler S, Abdel-Halim M, Fathalla RK, Da Silva LM, Keeton AB, Maxuitenko YY, Berry KL, Zhou G, Engel M, Abadi AH, Piazza GA. Sigler S, et al. Among authors: maxuitenko yy. Anticancer Agents Med Chem. 2025;25(1):52-62. doi: 10.2174/0118715206318802240821114353. Anticancer Agents Med Chem. 2025. PMID: 39225209
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma.
Reddy Bandi DS, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, Fang YD, Keeton AB, Chen X, Berry KL, Bae S, Akce M, Gorman G, Yoon KJ, Manne U, Boyd MR, Buchsbaum DJ, Azmi AS, Maxuitenko YY, Piazza GA, El-Rayes BF. Reddy Bandi DS, et al. Among authors: maxuitenko yy. bioRxiv [Preprint]. 2024 Oct 8:2024.10.04.616725. doi: 10.1101/2024.10.04.616725. bioRxiv. 2024. Update in: Mol Cancer. 2025 Mar 13;24(1):76. doi: 10.1186/s12943-025-02288-9. PMID: 39416034 Free PMC article. Updated. Preprint.
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Bandi DSR, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, Fang YD, Keeton AB, Chen X, Valiyaveettil J, Berry KL, Bae S, Akce M, Gorman G, Yoon KJ, Manne U, Boyd MR, Buchsbaum DJ, Azmi AS, Maxuitenko YY, Piazza GA, El-Rayes BF. Bandi DSR, et al. Among authors: maxuitenko yy. Mol Cancer. 2025 Mar 13;24(1):76. doi: 10.1186/s12943-025-02288-9. Mol Cancer. 2025. PMID: 40082968 Free PMC article.
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. Ward AB, et al. Among authors: maxuitenko yy. MedComm (2020). 2020 Sep;1(2):121-128. doi: 10.1002/mco2.10. Epub 2020 Jun 25. MedComm (2020). 2020. PMID: 33073260 Free PMC article.
22 results